Single-cell RNA sequencing analysis showed that the intratumoral immunomodulation of CD73 inhibition is distinct from PD-1 inhibition and exhibits potential as a novel anticancer immunotherapy for CRC [13]. This evidence concerns the gene NT5E and colorectal carcinoma.